30 closest matches · ranked by relevance
Developmental and/or Epileptic Encephalopathies
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the…
Epileptic Encephalopathy · Continuous Spike and Wave During Sleep
Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326
Epilepsy
Primary: Functional Connectivity
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Percent Change From Baseline in Seizure Frequency Per 28 Days During the Maintenance Period — 3.11; -27.76 percent change — p=0.0007
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
Hypoxic-Ischemic Encephalopathy · Brain Injury · Neonatal Seizure
Primary: Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality. — 28 Participants
Epilepsy
Primary: Summary of 28-day Seizure Frequency for Sum of Individual Seizures and Clusters for 52-week OLE Period (Mean Percent Change & Standard Deviation) — -31.23; NA; 122.10…
Epilepsy
Primary: Completed MEG — 1 participants
Epilepsy · Non-Epileptic Seizure
Primary: Inter-rater Agreement of the International Federation of Clinical Neurophysiology (IFCN) Criteria (Cut-off=4) in Sensor Space and of Detection of Epileptiform Discharges…
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Elderly · Epilepsy · Seizures
Primary: Effectiveness of Medication as Measured by Participation Through the End of the Trial. — 14 participants
Mitochondrial Disease · Neurology · Myopathy
Primary: Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Baseline — 23.9; 20.4 Units on a scale
Childhood Absence Epilepsy · Petit Mal Epilepsy · Epilepsy
Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001
Dravet Syndrome · Lennox Gastaut Syndrome · Epileptic Encephalopathy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 75.5 percentage of participants
Pediatric Epilepsy · Epilepsy Surgery · High Frequency Oscillation
Primary: Post-operative Seizure-free Rate — 4; 5; 4; 4 Participants
Neonatal Encephalopathy · Hypoxic-Ischemic Encephalopathy Mild
Primary: Normal Neurodevelopment — 13; 14 Participants
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group — 306; 353; 135; 140 participants
CDKL5 Deficiency Disorder
Primary: Summary of 28-day Seizure Frequency for Major Motor Seizure Types — 49.17; 54.00; 55.50; 45.03 Seizures per day
Epilepsy · Tumor · Healthy
Primary: Localizing Brain Regions That Generate Interictal Spikes — 52 Participants
Neonatal Seizures
Primary: WIDEA Neurodevelopmental Outcome Score — 149.04; 162.46; 148.80; 151.89 score on a scale
Epilepsy
Primary: Percent Change From Baseline in 28-Day Convulsive Seizure Frequency During Ataluren Treatment Period — 723.17 percent change
Epilepsy
Primary: Change From Baseline in Weight Z-score up to Month 1 — -0.112; -0.014 Z-score
Sturge-Weber Syndrome
Primary: List Sorting Working Memory Test — 37.14; 39.14 T-score
CDD
Primary: Change From Baseline in Median Monthly Convulsive Seizure Frequency — 88.429 Number of monthly seizures
Seizures
Primary: Percentage of Participants With Adverse Events — 88.9; 92.3; 88.2; 90.4 Percentage of participants
Neonatal Seizures
Primary: Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg) — 15; 24 Participants — p=<0.001
Dravet Syndrome (DS)
Primary: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment Period — -8.64; -22.16 percent change — p==0.061
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001